

NAACCR 2010 Call for Data

Data Selection Criteria Based on Case Reportability

1995-2007

The data selection criteria for use in identifying cases for inclusion in data submissions for CINA or registry certification have been developed to exactly match the NPCR Call for Data case definition.

Diagnosis Years: Include cases diagnosed in all residents of your catchment area beginning with your reference year (e.g., 1995) through December 31, 2007. For guidance on residency, refer to page 21 of NAACCR Standards for Cancer Registries, Volume II, Record Layout Version 11.3 (April 2008)

Reportable Diagnoses: All histologies with a behavior code of “2” or “3” (or in some cases behavior “0” or “1”, see table 1 and table 2 for details) in the *International Classification of Diseases for Oncology*, Third Edition (ICD-O-3) are included with the exceptions specified below.

Exclusion Criteria

Exclude neoplasms of the skin (C44.0–C44.9) with the following histologies.

Do not exclude skin lesions that occur at the mucoepidermoid sites [vagina (C52.9), clitoris (C51.2), vulva (C51.0-51.9), prepuce (C60.0), penis (C60.9) , and scrotum (C63.2)]:

8000-8005 Neoplasms, malignant, NOS of the skin (C44.0-C44.9)

8010-8046 Epithelial carcinomas of the skin (C44.0-C44.9)

8050-8084 Papillary and squamous cell carcinomas of the skin (C44.0-C44.9)

8090-8110 Basal cell carcinomas of the skin (C44.0-C44.9)

Exclude, carcinoma in situ of the cervix (C53.0-C53.9 any morphology and/2) after January 1, 1996.

Exclude prostate intraepithelial neoplasia, grade III (PIN III) (C61.9. 8148/2) after January 1, 2001.

Exclude squamous intraepithelial neoplasia, grade III (8077/2) of the following sites: anus (C21.0 and C21.1, AIN III), cervix (C53, CIN III), vagina (C52.9, VAIN III), and vulvar (C51, VIN III).

Inclusion Criteria

The cases to be included reflect standards for reportability during the year of diagnosis and vary by year of diagnosis as a result. These changes are based upon NPCR and NAACCR reportable condition standards and changes in behavior coding between ICD-O 2 and ICD-O 3.

The following histologies should be reported for all cases diagnosed prior to January 1, 2001. These histologies are generally coded to ovary (C56.9), but are not limited to this primary site.

Table 1 Required Histological Diagnoses Considered Invasive under ICD-O 2 and not ICD-O 3

Descriptive terms and topography codes	ICD-O-2	ICD-O-3
Serous cystadenoma, borderline malignancy (C56.9)	8442/3	8442/1
Serous tumor, NOS, of low malignant potential (C56.9)	8442/3	8442/1
Papillary cystadenoma, borderline malignancy (C56.9)	8451/3	8451/1
Serous papillary cystic tumor of borderline malignancy (C56.9)	8462/3	8462/1
Papillary serous cystadenoma, borderline malignancy(C56.9)	8462/3	8462/1
Papillary serous tumor of low malignant potential(C56.9)	8462/3	8462/1
Atypical proliferative papillary serous tumor(C56.9)	8462/3	8462/1
Mucinous cystic tumor of borderline malignancy(C56.9)	8472/3	8472/1
Mucinous cystadenoma, borderline malignancy(C56.9)	8472/3	8472/1
Pseudomucinous cystadenoma, borderline malignancy(C56.9)	8472/3	8472/1
Mucinous tumor, NOS, of low malignant potential(C56.9)	8472/3	8472/1
Papillary mucinous cystadenoma, borderline malignancy (C56.9)	8473/3	8473/1
Papillary pseudomucinous cystadenoma, borderline malignancy(C56.9)	8473/3	8473/1
Papillary mucinous tumor of low malignant potential(C56.9)	8473/3	8473/1
Pilocytic astrocytoma (C71._)	9421/3	9421/1
Piloid astocytoma (C71._)		
Juvenile astrocytoma (C71._)		
Spongiblastoma, NOS (C71._)	9422/3	9421/1

Depending on the date of diagnosis, the primary site and morphology must be coded according to the ICD-O-2 or ICD-O-3 coding system. The primary site codes did not change from ICD-O-2 to ICD-O-3.

REMINDER: Convert your pre-2001 ICD-O-2 morphology data to the corresponding ICD-O-3 codes. Conversion programs are available at <http://seer.cancer.gov/tools/conversion/>.

Cases diagnosed beginning January 1, 2004: All nonmalignant primary intracranial and central nervous system tumors with a behavior code of “0” or “1” are reportable. However, benign and borderline tumors of the cranial bones (C410) are not reportable. For further guidance, please refer to the following table

Table 2. Required Sites for Benign and Borderline Primary Intracranial and Central Nervous System Tumors

General Term	Specific Sites	ICD-O-3 Topography Code
Meninges	Cerebral meninges	C70.0
	Meninges, NOS	C70.9
	Spinal meninges	C70.1
Brain	Cerebrum	C71.0
	Frontal lobe	C71.1
	Temporal lobe	C71.2
	Parietal lobe	C71.3
	Occipital lobe	C71.4

	Ventricle, NOS	C71.5
	Cerebellum, NOS	C71.6
	Brain stem	C71.7
	Overlapping lesion of brain	C71.8
	Brain, NOS	C71.9
Spinal cord, cranial nerves, and other parts of the central nervous system	Spinal cord C720	C72.0
	Cauda equine	C72.1
	Olfactory nerve	C72.2
	Optic nerve	C72.3
	Acoustic nerve	C72.4
	Cranial nerve, NOS	C72.5
	Overlapping lesion of brain and central nervous system	C72.8
	Nervous system, NOS	C72.9
Pituitary, craniopharyngeal, duct, and pineal Gland	Pituitary gland	C75.1
	Craniopharyngeal duct	C75.2
	Pineal gland	C75.3

Collaborative Stage Version

For cases diagnosed beginning January 1, 2004, report the derived Summary Stage 2000 [NAACCR data item #3020] using the Collaborative Staging (CS) Algorithm version 01.04.00 or later.